AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma - LARVOL DELTA

Efficacy and Safety of HS-10370 Combined With Adebrelimab and Chemotherapy in First-Line Advanced KRAS G12C-Mutated NSCLC (IASLC-WCLC 2026) - P1 | "Methods : Treatment-naïve pts with locally advanced/metastatic non-squamous NSCLC and KRAS G12C mutation received HS-10370 (400 mg or 800 mg) orally once daily, adebrelimab (20 mg/kg) intravenously every 3 weeks (Q3W), and pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC 5 mg/ml/min) intravenously Q3W (4-6 cycles for platinum-based drugs), until disease progression or unacceptable toxicity. Conclusions : HS-10370 in combination with adebrelimab and platinum-based chemotherapy demonstrated a manageable safety profile and promising anti-tumor activity as 1L treatment for advanced NSCLC with KRAS G12C mutation across all PD-L1 expression levels. These findings suggest a longer survival follow-up for RP3D determination and further evaluation in a randomized phase 3 trial."

Clinical • IO biomarker • Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Neutropenia • Non Small Cell Lung Cancer • Solid Tumor • KRAS

The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. (PubMed, J Hematol Oncol) - "This correspondence highlights how the first-in-class pan-RAS (ON) inhibitor daraxonrasib (RMC-6236) virtually doubled median overall survival (13.2 vs. 6.6 months) and progression-free survival compared to chemotherapy in second-line mPDAC, establishing a new standard of care...These include the selective KRAS G12D inhibitor DN022150 and promising horizontal combinations pairing the G12D inhibitor HRS-4642 with either the anti-PD-L1 antibody adebrelimab or a Nectin-4-targeted antibody-drug conjugate (ADC). Furthermore, we address the KRAS G12C cohort where farnesyl transferase co-inhibition (darlifarnib plus adagrasib) successfully bypasses adaptive resistance. Ultimately, the therapeutic landscape of mPDAC is transitioning toward tailored genomic frameworks. Future success will rely on optimizing the clinical sequencing or combination of pan-RAS and allele-specific agents, guided by real-time liquid biopsies, to permanently dismantle resistance and transform mPDAC into..."

IO biomarker • Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS

HRS-4642 Plus Chemotherapy ± Adebrelimab as Perioperative Therapy in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Results of a Phase 2 Study (ESMO 2026) - No abstract available

Late-breaking abstract • P2 data • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Hypofractionated Partial Tumor Irradiation Followed by Adebrelimab Combined with Chemotherapy as Induction Therapy before Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (ESMO 2026) - No abstract available

Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer: A single-arm, prospective phase II trial (ESMO 2026) - No abstract available

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Preliminary results from Phase II trial of perioperative Adebrelimab combined with XELOX in resectable locally advanced gastric/gastroesophageal junction cancer (PAXGC study) (ESMO 2026) - No abstract available

Metastases • P2 data • Oncology • Solid Tumor

Anti-HER3 Antibody-Drug Conjugate (ADC) SHR-A2009 plus Adebrelimab in Immunotherapy-Treated Advanced Esophageal Squamous Cell Carcinoma (ESCC): Cohort D Results from the CAP 02 Study (ESMO 2026) - No abstract available

ADC • Metastases • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Tislelizumab Combined with Chemotherapy Followed by Consolidative Thoracic Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study (ASTRO 2026) - P2 | "A phase II prospective trial investigated adebrelimab (a PD-L1 antibody) plus first-line chemotherapy followed by TRT combined with adebrelimab in ES-SCLC.The study demonstrated promising efficacy (mOS 21.4 months and median progression-free survival [mPFS] 10.1 months, respectively) and safety in ES-SCLC...All patients will receive 4 to 6 cycles of induction therapy with tislelizumab combined with etoposide plus platinum-based chemotherapy... The trial is currently ongoing."

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Hepatic arterial infusion chemotherapy plus adebrelimab and bevacizumab as conversion therapy for hepatocellular carcinoma: an investigator-initiated phase II study (ESMO 2026) - No abstract available

P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Adebrelimab as Maintenance Therapy Following Hyperfractionated Simultaneous Integrated Boost Radiotherapy Plus Chemotherapy in Limited-Stage Small-Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Phase II Trial (ASTRO 2026) - P2 | "Materials/ This prospective, multicenter, single-arm Phase II trial enrolled patients with unresectable LS-SCLC who achieved progression-free status after concurrent chemoradiotherapy (cCRT), consisting of etoposide-platinum plus platinum chemotherapy and HSIB radiotherapy (54 Gy/30 fractions). Maintenance adebrelimab following cCRT with HSIB radiotherapy demonstrated excellent tolerability and promising disease control in LS-SCLC. These results provide the first evidence supporting the safe integration of maintenance immunotherapy with HSIB radiotherapy."

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Maintenance therapy with adebrelimab plus apatinib in extensive-stage small-cell lung cancer: a prospective, multicentre, single-arm phase II study (ESMO 2026) - No abstract available

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Preoperative Short-Course Radiotherapy Followed by Chemotherapy and PD-L1 Inhibitor for Locally Advanced Rectal Cancer: A Prospective Phase II Study (ASTRO 2026) - "SCRT combined with Adebrelimab and chemotherapy demonstrated promising efficacy and manageable toxicity in LARC, supporting further investigation in randomized trials."

Clinical • Metastases • P2 data • Colorectal Cancer • Microsatellite Instability • Oncology • Rectal Cancer • Solid Tumor • MSI

Perioperative HRS-4642, Chemotherapy, and Adebrelimab in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Phase 2 Results (ESMO 2026) - No abstract available

P2 data • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Two versus Four Cycles of Neoadjuvant Adebrelimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter, Randomized Phase II Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

SHR-A1904 plus adebrelimab with/without 5-FU as 1L therapy for CLDN18.2+ advanced GC/GEJC: data from a phase Ib/III study (ESMO 2026) - No abstract available

Metastases • Gastric Cancer • Oncology • CLDN18

Adebrelimab combined with albumin-bound paclitaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a multi-center, single-arm clinical trial (AURORA-NEO) (ESMO 2026) - No abstract available

Clinical • Metastases • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

SHR-A2009 plus adebrelimab (Adebre) with or without bevacizumab (Bev) for pretreated NSCLC: a phase 1b/2 study (ESMO 2026) - No abstract available

P1/2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

SHR-A1811 ± adebrelimab (Adebre) for HER2-overexpressing advanced NSCLC: results from a phase 1b/2 study (ESMO 2026) - No abstract available

Metastases • P1/2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

HRS-4642 Combined with Adebrelimab and Chemotherapy as Firstline Treatment for KRAS G12D Mutant Advanced Non-small Cell Lung Cancer: A Phase 1b/2 Study (ESMO 2026) - No abstract available

Clinical • Metastases • P1/2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Adebrelimab plus Bevacizumab and Nab-paclitaxel in Non-squamous NSCLC after Progression on First-line ICI-based therapy: A Phase II Rechallenge Study with Biomarker Analysis (ESMO 2026) - No abstract available

Biomarker • Clinical • P2 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Adebrelimab combined with Anlotinib and Chemotherapy Neoadjuvant Therapy Resectable Stage II-III Non-Small Cell Lung Cancer (ESMO 2026) - No abstract available

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A randomized, open-label, multicenter phase II study of SHR-8068 plus adebrelimab and gemcitabine/cisplatin (GC) as first-line treatment for advanced biliary tract cancer (BTC) (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=84 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. (PubMed, Cancer Cell) - P1/2 | "In the RP2D cohort (n = 37), the confirmed objective response rate was 43.2% (95% confidence interval [CI], 27.1-60.5), disease control rate was 81.1% (95% CI, 64.8-92.0), median duration of response was 6.9 months (95% CI, 4.8-8.6), median progression-free survival was 5.7 months (95% CI, 4.0-7.5), and median overall survival was 11.5 months (95% CI, 9.2-16.9). This chemotherapy-free regimen is tolerable and shows encouraging antitumor activity in refractory KRAS G12D-mutant PDAC, warranting further investigation."

IO biomarker • Journal • P1/2 data • Dyslipidemia • Hematological Disorders • Metabolic Disorders • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS

Adebrelimab Plus Ivarmacitinib With or Without Chemotherapy as First-Line Treatment for Advanced NSCLC: A Phase 2 Trial (IASLC-WCLC 2026) - P2, P4 | "First-line pembrolizumab plus itacitinib (NCT03425006) resulted in a 12-week objective response rate (ORR) of 62% and a median progression-free survival (PFS) of 15.6 months in 23 patients with metastatic NSCLC and PD-L1 tumor proportion score (TPS) ≥50%...Cohort B will additionally receive platinum-based doublet chemotherapy for 2 cycles (if pemetrexed is used for non-squamous NSCLC, it will be continued until disease progression or intolerable toxicity) since the initiation of adebrelimab treatment...The 95% confidence intervals (CIs) of ORR and DCR will be calculated using the Clopper-Pearson method. Median survival will be estimated using the Kaplan-Meier method, and the corresponding 95% CIs will be calculated using the Brookmeyer-Crowley method."

Clinical • IO biomarker • Metastases • P2 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • CD8 • EGFR • MET • ROS1